Disc Medicine Inc. Cash Flow Conversion Efficiency
Disc Medicine Inc. cash flow conversion efficiency. Based on the latest financial reports, Disc Medicine Inc. (IRON) has a cash flow conversion efficiency ratio of -0.069x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.20 Million) by net assets ($644.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Disc Medicine Inc. (2020–2025)
Cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2025. This chart illustrates how Disc Medicine Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Disc Medicine Inc. stock price today for real-time trading data and today's change.
Disc Medicine Inc. Cash Flow Conversion Ratio Explained
Disc Medicine Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Disc Medicine Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Disc Medicine Inc. ranked by their cash flow conversion efficiency. Also see IRON market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dalmia Bharat Limited
NSE:DALBHARAT
|
0.041x |
|
Joincare Pharmaceutical Group Industry Co Ltd
SHG:600380
|
0.046x |
|
Gold Road Resources Ltd
AU:GOR
|
0.122x |
|
China International Marine Containers (Group) Co. Ltd
F:OCM
|
0.009x |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
OLAM GROUP LTD
F:K25
|
N/A |
|
FRASERS PROPERTY
F:1IQ
|
N/A |
|
Bandhan Bank Limited
NSE:BANDHANBNK
|
-0.323x |
Annual Cash Flow Conversion Efficiency for Disc Medicine Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Disc Medicine Inc. from 2020 to 2025. Review IRON free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $739.83 Million | $-180.39 Million | -0.244x | -15.16% |
| 2024-12-31 | $443.59 Million | $-93.93 Million | -0.212x | +0.52% |
| 2023-12-31 | $345.12 Million | $-73.46 Million | -0.213x | +11.03% |
| 2022-12-31 | $176.60 Million | $-42.25 Million | -0.239x | -155.79% |
| 2021-12-31 | $-64.20 Million | $-27.53 Million | 0.429x | -71.34% |
| 2020-12-31 | $-21.86 Million | $-32.71 Million | 1.496x | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more